Tumor-Infiltrating Lymphocytes & Tumor-Specific Antigens

June 10, 2022 | 1 - 3 p.m. CT

This Professional Development Café will be hosted by ASGCT Associate Member Vincenzo Cerullo, PhD.

Registrants: Watch the Event On Demand

Dr. Cerullo will discuss tumor-infiltrating lymphocytes (TILs), an experimental cell therapy being developed for treating solid tumors, and tumor-specific antigens (TSAs), which can help the body make an immune response against cancer cells. View the event in your time zone.

During this presentation, Dr. Cerullo will:

  • Describe a compelling pipeline that encompasses the complete tumor antigen discovery directly from resected tumors or even tumor organoids

  • Explain novel approaches to identify and prioritize tumor associated antigens and tumor neo antigens

  • Share inexpensive and flexible approaches to developing and testing precision gene immunotherapies and oncolytic vaccines

About the Presenter

Dr. Cerullo is professor of biological drug development at the University of Helsinki. He got his PhD at the Centre for Genetic Engineering (CENIGE) at the University of Naples. He then moved to Houston for a postdoc at Baylor College of Medicine. In 2009, he moved to the University of Helsinki where he worked as senior researcher. In 2012, Dr. Cerullo was awarded the tenure-track professorship and started the ImmunoViroTherapy Lab. In these years IVTLab raised more than 5 million Euros for research, including the prestigious ERC Consolidator Grant, HiLIFE fellow and Jane and Aatos Erkko Foundation grant. The group has produced numerous scientific papers and patents and has co-founded a spin-off company together with the University of Helsinki (VALO Therapeutics).

Dr. Cerullo has been awarded the 2014 Outstanding Young Investigator Award from the European Society of Gene and Cell Therapy (ESGCT) and a 2015 Excellence in Research Award from ASGCT.

A recording to this café will be available following its live production.


ASGCT Policy Summit

Watch On Demand Through Oct. 27

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.